ArticleNature medicine2011
Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells.
Article in Nature medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 470 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
470 citing papers in PubMed, 4 syntheses or guidelines pooled it, 904 citations in OpenAlex.
- Fasting appetite-related gut hormone responses after weight loss induced by calorie restriction, exercise, or both in people with overweight or obesity: a meta-analysis.International journal of obesity (2005) · 2025Pooled it
- Clinical outcome changes in sarcopenic obesity: a meta-analysis of exercise training methods.BMC geriatrics · 2025Pooled it
- Systematic Review ofInternational journal of molecular sciences · 2024Pooled it
- Managing diabetes in diabetic patients with COVID: where do we start from?Acta diabetologica · 2021Pooled it
- Acute interleukin-1β antagonism decreases systemic inflammation, increases GLP-1 release, and modulates insulin secretion in individuals with prediabetes.American journal of physiology. Endocrinology and metabolism · 2026Trial
- Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-RichNutrients · 2025Trial
- Combined training and hormones/enzymes with insulinotropic actions in individuals with overweight and type 2 diabetes mellitus: A randomized controlled trial.European journal of sport science · 2024Trial
- Prolonged lipopolysaccharide-induced illness elevates glucagon-like peptide-1 and suppresses peptide YY: A human-randomized cross-over trial.Physiological reports · 2022Trial
- Exerkines in precision management of metabolic diseases.Chinese medical journal · 2026Review
- Elevated endogenous glucagon-like peptide-1 as a novel Alzheimer's disease biomarker associated with neuroinflammation and Aβ pathology.General psychiatry · 2026Article
- β-cell 14-3-3-ζ and sex are key regulators of α-cell form and function.Endocrinology · 2026Article
- Exerkine-Mediated Inter-Organ Crosstalk and Translational Perspectives in Metabolic Diseases.Current obesity reports · 2026Review
- Advances in Exercise-Mediated Regulation of the Gut Microbiota via the Muscle-Gut Axis: Implications for Tumor Immunity and Treatment Responses.Metabolites · 2026Review
- Pancreatic islets: new discoveries for innovative treatments of diabetes?Diabetologia · 2026Review
- Changes in GLP-1 and GIP During Endurance Training in Competitive Triathletes: A Pilot Observational Study.Journal of clinical medicine · 2026Article
- Pancreatic Islet Cell Crosstalk: Insight Into α-/β-Cell Compensatory Mechanisms.Comprehensive Physiology · 2026Article
- Acute and resolving inflammation differentially regulates beta cell function in mice via interactions between peritoneal and islet-associated macrophages.Diabetologia · 2026Article
- GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease.Nature reviews. Nephrology · 2026Review
- Semaglutide-Induced Symptomatic Remission in Ulcerative Colitis.ACG case reports journal · 2026Article
- Article
410 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
21 authors at 8 institutions in 4 countries.
Funding
Abstract
Exercise, obesity and type 2 diabetes are associated with elevated plasma concentrations of interleukin-6 (IL-6). Glucagon-like peptide-1 (GLP-1) is a hormone that induces insulin secretion. Here we show that administration of IL-6 or elevated IL-6 concentrations in response to exercise stimulate GLP-1 secretion from intestinal L cells and pancreatic alpha cells, improving insulin secretion and glycemia. IL-6 increased GLP-1 production from alpha cells through increased proglucagon (which is encoded by GCG) and prohormone convertase 1/3 expression. In models of type 2 diabetes, the beneficial effects of IL-6 were maintained, and IL-6 neutralization resulted in further elevation of glycemia and reduced pancreatic GLP-1. Hence, IL-6 mediates crosstalk between insulin-sensitive tissues, intestinal L cells and pancreatic islets to adapt to changes in insulin demand. This previously unidentified endocrine loop implicates IL-6 in the regulation of insulin secretion and suggests that drugs modulating this loop may be useful in type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.